Geron (GERN) Q4 2025 earnings summary

Executive summary

• Strategic realignment and restructuring in 2025 positioned the company for commercial growth in 2026, focusing on RYTELO in second-line, lower-risk MDS patients.

• Leadership team strengthened, commercial strategy refined, and financial discipline improved to support growth priorities.

• RYTELO net revenue reached $48M in Q4 2025 and $184M for the full year, reflecting strong commercial uptake in its first full commercial year.

• RYTELO demand grew 9% sequentially in Q4 2025, with ordering accounts increasing to approximately 1,300.

• Expanded scientific evidence for RYTELO with new publications and presentations, reinforcing its differentiated profile in LR-MDS.

Financial highlights

• Q4 2025 net revenue was $48M, up from $47M in Q4 2024; full year 2025 net revenue was $184M, up from $76M in 2024.

• Total operating expenses for 2025 were $255M, within guidance of $250M-$260M.

• Gross to net deductions rose to 17.7% in 2025 from 14.5% in 2024, reflecting increased 340B utilization and GPO contracting.

• R&D expenses decreased to $74M in 2025 from $104M in 2024 due to lower clinical trial and manufacturing costs.

• Ended 2025 with $401M in cash, cash equivalents, restricted cash, and marketable securities.

Outlook and guidance

• 2026 RYTELO net revenue expected between $220M-$240M, with growth weighted to the second half of the year.

• 2026 total operating expenses projected at $230M-$240M, reflecting a $20M year-over-year reduction at midpoint.

• Gross to net expected in the high teens to low twenties for 2026.

• Existing cash and anticipated revenues expected to fund operations for the foreseeable future.

• Continued investment in commercial strategy and ISTs prioritized over immediate profitability.